Tuesday, September 1, 2026

Sorrento Therapeutics Stock Bearish Momentum With A 16% Slide In The Last 5 Sessions

Sorrento Therapeutics Stock Bearish Momentum With A 16% Slide In The Last 5 Sessions

(VIANEWS) - Shares of Sorrento Therapeutics (NASDAQ: SRNE) slid by a staggering 16.22% in 5 sessions from $0.37 at -16.22, to $0.31 at 23:23 EST on Wednesday, after five sequential sessions in a row of losses. NASDAQ is falling 0.85% to $11,929.34, after three sequential sessions in a row of losses.

Sorrento Therapeutics's last close was $0.35, 88.82% below its 52-week high of $3.09.

About Sorrento Therapeutics

Earnings Per Share

As for profitability, Sorrento Therapeutics has a trailing twelve months EPS of $-1.3.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -378.92%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Sorrento Therapeutics's stock is considered to be overbought (>=80).

Moving Average

Sorrento Therapeutics's value is way below its 50-day moving average of $0.77 and way below its 200-day moving average of $1.55.

Sales Growth

Sorrento Therapeutics's sales growth is 32.2% for the present quarter and 8.8% for the next.

Revenue Growth

Year-on-year quarterly revenue growth grew by 44.3%, now sitting on 60.32M for the twelve trailing months.

More news about Sorrento Therapeutics (SRNE).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge: Late-August 2026 Funding Wave Spans Fintech, Enterprise Agents, and Robotics
A dense cluster of funding rounds landing on 2026-08-28 — from identity/fraud fintech player Socure ($156M plus its acquisition of Fravity) to enterprise AI agent startups (Instinct, Generalist AI, Owner), model infrastructure (Stability AI, Emerald AI), and autonomous logistics/aerospace (Gatik, Regent Craft) — signals investors are rotating aggressively into AI-native companies with demonstrable ROI, especially in financial risk/compliance and back-office automation. Parallel signals (Multiverse Computing's compression benchmarks cutting inference cost/latency, and Arkestro/CloneOps.ai publishing hard savings and labor-displacement figures) suggest the funding is chasing efficiency and measurable economic impact rather than pure model scale.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,980
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,980 facts checked against source5,267 source documents archived
Query this data → isubstrate.com